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Although several specific micronutrient deficiencies are associated with disease progression and 
increased mortality risk in HIV/AIDS, and even a simple multivitamin/mineral supplement can 
prolong survival, this is typically viewed merely as nutritional support of the immune system, 
and only necessary if there are deficiencies to be rectified. However, the reality is more complex. 
Several striking nutrient-related metabolic abnormalities have been consistently documented in 
HIV infection. One is chronic oxidative stress, including a drastic depletion of cysteine from the 
glutathione pool, and a progressive decline of serum selenium that is correlated with disease 
progression and mortality. Another is decreased blood levels of tryptophan, with an associated 
intracellular niacin deficiency. Tryptophan depletion or “deletion” by induction of indoleamine-
2,3-dioxygenase (IDO), the first step in oxidative tryptophan metabolism, is a known mechanism 
for immune suppression that is of critical importance in cancer and pregnancy, and, potentially, 
in HIV/AIDS. Existing evidence supports the hypothesis that these nutrient-related metabolic 
abnormalities in HIV infection regarding antioxidants, selenium, sulfur, tryptophan and niacin 
are interrelated, because HIV-associated oxidative stress can induce niacin/NAD+ depletion via 
activation of poly(ADP-ribose) polymerase (PARP), which could lead to tryptophan oxidation 
for compensatory de novo niacin synthesis, thereby contributing to immune tolerance and T-cell 
loss via tryptophan deletion and PARP-induced cell death. This “oxidative stress-induced niacin 
sink” (OSINS) model provides a mechanism whereby the oxidative stress associated with HIV 
infection can contribute to immunosuppression via tryptophan deletion. This model is directly 
supported by evidence that antioxidants can counteract indoleamine-2,3-dioxygenase (IDO), 
providing the critical link between oxidative stress and tryptophan metabolism proposed here. 
The OSINS model can be used to guide the design of nutraceutical regimens that can effectively 
complement antiretroviral therapy for HIV/AIDS. 
 





1. Introduction: dietary factors, deficiencies and supplementation in HIV/AIDS 
 
The use of vitamins, minerals, amino acids and other dietary supplements is widespread in HIV-
infected populations, and not surprisingly, many such products are promoted as complementary-
alternative medicine therapies by some supplement manufacturers and vendors, and aggressively 
marketed on the Internet. Unfortunately, but not unexpectedly, this has led to a backlash against 
the concept of HIV nutritional therapy in general. 
 
Yet there is extensive evidence that certain micronutrient deficiencies are associated with faster 
disease progression or increased mortality risk, and that dietary supplements (e.g. a daily 
multivitamin) can prolong survival in HIV/AIDS (reviewed below). To establish the scientific 
basis of complementary nutritional therapies for HIV, there is an urgent need for mechanistic 
studies of promising nutraceutical compounds, and more evidence-based research to determine 
their potential for help or harm in HIV infection. 
 
Numerous studies have demonstrated that the intake or blood levels of various micronutrients are 
significantly correlated with disease progression or outcome (i.e., survival vs. mortality) in HIV-
1 infection (Abrams et al., 1993, Baum and Shor-Posner, 1998, Baum et al., 1997a, Baum et al., 
1997b, Constans et al., 1995, Tang et al., 1993, Tang et al., 1996). These nutrients include B 
vitamins, antioxidant vitamins, zinc and selenium; similar correlations exist for nutrition-
dependent biomolecules like the antioxidant glutathione, which requires the amino acid cysteine, 
which becomes depleted in HIV infection (Droge, 1993, Eck et al., 1989). 
 
In countries where malnutrition is common, some studies document significantly lower levels of 
multiple trace minerals in HIV-infected subjects relative to uninfected controls, e.g., in Ethiopian 
HIV-infected pregnant women, deficiencies in zinc, magnesium, and selenium were found to be 
significantly greater than those in HIV-seronegative women, pregnant or otherwise (Kassu et al., 
2008). In a recent Nigerian study, with the exception of zinc, all of the trace elements (Mg, Fe, 
Mn, Cu, Cr and Se) were significantly lower in HIV-infected patients compared to healthy 
controls (Olaniyi and Arinola, 2007). Such deficiencies in trace minerals can have far-reaching 
biochemical effects, given the ubiquitousness of metalloenzymes, but for the purposes of this 
review, one aspect stands out in importance: the potential relationship to oxidative stress. In 
addition to the antioxidant role of selenium in glutathione peroxidases, zinc, copper and 
manganese are essential components of the Cu/Zn and Mn superoxide dismutases, and zinc also 
plays roles in the repair of oxidant-induced DNA damage (Song et al., 2009). 
 
Iron presents unique problems, because anemia is common in the developing world, suggesting a 
need for iron supplementation, yet elevated iron status is actually more dangerous in HIV 
infection, as it is a strong predictor of HIV-related mortality (McDermid et al., 2007). This is not 
surprising, as excess free iron can lead to increased production of superoxide and hydroxyl 
radical via the Fenton reaction; as will be discussed below, these molecular species can 
potentially contribute to HIV activation and pathogenesis. 
 
As reviewed by Fawzi et al. (2005), various observational studies and randomized trials have 
shown that daily multivitamin supplements can reduce HIV disease progression and mortality 
(Fawzi et al., 2004, Jiamton et al., 2003, Kanter et al., 1999). As an example, in a Bangkok study 
reported in 2003, the participants, all HIV positive and not on antiretroviral drug therapy, were 
given either a placebo or a daily multivitamin that included 400 mcg of selenium. The results 
showed a significant survival benefit for those taking the supplement, particularly for those who 
had the lowest CD4 cell counts; for study participants with a CD4 count under 100, those in the 
placebo group were 4 times as likely to die as those who were taking the supplement (Jiamton et 
al., 2003). 
 
A study by Hurwitz et al. (2007) suggested that, in HIV+ subjects who were compliant, a daily 
supplement of 200 μg of selenium alone stopped progression of HIV-1 viral load increases, and 
lead to improved CD4 counts. This is consistent with previous retrospective studies suggesting 
that, of all the nutrients studied, selenium stands out as a powerful predictor of outcome in HIV 
infection; in one study, selenium status was reported to be 10 times more significant than CD4 
cell count as a predictor of mortality (Baum et al., 1997a). In another randomized, double-
blinded, placebo-controlled trial, the co-administration of a trace mineral and antioxidant-rich 
supplement to patients on highly active antiretroviral therapy (HAART) led to significantly 
increased immune reconstitution at 12 weeks, as indicated by a 24% increase in absolute CD4 
count in the micronutrient group, versus a 0% change in the (HAART-only) placebo group 
(P = 0.01); (Kaiser et al., 2006). 
 
A comprehensive retrospective of the evidence for the role of nutritional factors in HIV disease 
pathogenesis and treatment is not my goal here, as there are already a number of recent reviews, 
some focused on specific nutrients or types of nutrients, and others looking at the broader 
spectrum of nutrition in HIV/AIDS (Allard et al., 1998, Baum, 2000, Baum and Shor-Posner, 
1998, Coodley et al., 1993, Drain et al., 2007, Fawzi et al., 2005, Lanzillotti and Tang, 
2005, Patrick, 1999, Singhal and Austin, 2002, Tang et al., 1996, Taylor et al., 2000). 
 
The conventional viewpoint is that dietary supplementation is beneficial in HIV infection simply 
because certain micronutrients are particularly important for proper functioning of the immune 
system. However, the situation is much more complex. In this article, I will focus on several 
underlying metabolic nutrient-related abnormalities, to be presented below, that have been well 
documented in HIV infection, at both the cellular and systemic levels. A review of the literature 
suggests that certain key biochemical pathways of amino acid and micronutrient metabolism may 
play critical roles in producing or mediating these abnormalities, thus contributing to HIV 
pathogenesis. An understanding of the mechanisms involved is desirable for the optimization of 
nutrition-based complementary therapies, which also has the potential to permit the use of lower 
and less toxic doses of antiretroviral drugs, due to synergy of combined nutritional and drug 
therapies. The latter can be quite dramatic, e.g. as in the case of resveratrol and anti-HIV 
nucleosides (Heredia et al., 2000). 
 
2. Underlying mechanisms of nutrient-related metabolic abnormalities in HIV infection 
 
There are four biochemical systems or pathways of primary interest, and their interactions are 
illustrated in a simplified schematic diagram shown as Fig. 1. The significance of each of these 
biochemical systems in HIV disease will be briefly reviewed in subsequent subsections. These 
four systems include: 
 
• Redox status and antioxidant defenses, particularly as linked to sulfur (cysteine, 
glutathione) and selenium biochemistry; 
• Tryptophan metabolism, now understood to be a key immune regulatory system, with the 
potential to induce immune tolerance (e.g. to the fetus in pregnancy) and 
immunosuppression (Mellor et al., 2002, Mellor et al., 2003, Murray, 2003); 
• Arginine metabolism, which via nitric oxide (NO) and peroxynitrite production 
contributes to free radical biochemistry and thus interacts intimately with the antioxidant 
defense system, and which has also recently emerged as a critical biochemical pathway in 
the regulation of inflammation and immunity (Bansal and Ochoa, 2003, Brito et al., 
1999, Bronte et al., 2003, Bronte and Zanovello, 2005, Mills, 2001); 
• The poly(ADP-ribose) polymerase (PARP) complex, which can induce niacin/NAD+ 
depletion via its activation under oxidative stress (Cookson et al., 1998, Koh et al., 
2005, Tronov and Konstantinov, 2000, Virag, 2005), and thus is a point of intersection of 
the first three systems (see Fig. 1 and subsequent discussions for a full explanation). 
 
 
Figure 1. Illustration of the molecular basis of a link between four biochemical pathways involved in HIV-induced 
metabolic abnormalities: (1) antioxidants (Se, GPx, GSH) vs. ROS mediated oxidative stress (left); (2) tryptophan 
oxidation via the indoleamine-2,3-dioxygenase (IDO) pathway leading to immunosuppression by tryptophan 
deletion (right); (3) arginine metabolism, increased under cytokine induction of both iNOS and arginase, leading to 
increased peroxynitrite formation under arginine-limited conditions, and (4) the poly(ADP-ribose) polymerase 
(PARP) complex, which when activated by oxidative stress can induce niacin/NAD+ depletion, creating a demand 
for de novo niacin synthesis from tryptophan. This illustrates a potential mechanism whereby oxidative stress 
associated with HIV infection can contribute to immunosuppression by tryptophan deletion, and also to T-cell loss 
via PARP-induced necrosis and/or apoptosis. 
 
The clinically manifested HIV-associated nutrient-related metabolic abnormalities to which the 
above biochemical pathways contribute can be grouped into two major categories, as described 
in Sections 2.1 Chronic oxidative stress, sulfur metabolism and selenium deficiency in 
HIV/AIDS, 2.2 Tryptophan depletion in HIV infection: immunosuppression induced by 
tryptophan metabolism and its role in below. 
 




Probably the earliest noted antioxidant defect in HIV-infected patients was the apparent 
progressive decline in blood levels of the essential dietary antioxidant selenium (Se) that was 
first reported by Dworkin in the mid-1980s (Dworkin et al., 1985, Dworkin et al., 1986). This 
decline has been widely documented in many independent studies, as reviewed (Baum and Shor-
Posner, 1998, Campa et al., 2000, Constans et al., 1999, Taylor et al., 1997), and was generally 
found to be more severe in full-blown AIDS patients (Dworkin et al., 1988). This effect is even 
more pronounced during co-infection with hepatitis C virus (Look et al., 1997). Various 
retrospective studies demonstrated a correlation between serum selenium concentration and CD4 
T-cell counts (e.g., Beck et al., 1990, Look et al., 1997). Low serum selenium was eventually 
shown to be highly correlated with disease progression and increased mortality risk (e.g., Baum 




HIV infection is typically characterized by a dramatic decline in glutathione levels, even in 
asymptomatic individuals, first shown in the late 1980s (Buhl et al., 1989, Look et al., 1997). 
This is associated with an “alarming” negative sulfur balance (Breitkreutz et al., 2000), i.e., 
depletion of cysteine largely from the glutathione (GSH) pool, and its excretion as sulfate, 
contributing to the AIDS wasting syndrome (Breitkreutz et al., 2000, Droge et al., 1988, Droge et 
al., 1994, Eck et al., 1989). Note that this suggests an abnormal degree of biological oxidation, 
manifesting as elimination of cysteine sulfur as sulfate. 
 
A key feature of HIV disease is an apparent “antioxidant defect”, as proposed by Favier et al. 
(1994), which provides a novel perspective for understanding the role of many oxidative stress-
inducing cofactors that are known to accelerate the progression of AIDS. HIV infection can be 
aggravated by cofactors such as malnutrition, co-infection with other microorganisms, and the 
use of various oxidant drugs, such as nitrites. 
 
2.2. Tryptophan depletion in HIV infection: immunosuppression induced by tryptophan 
metabolism and its role in de novo niacin (NAD+) synthesis 
 
Significantly decreased blood levels of the essential amino acid tryptophan in infected 
individuals were noted fairly early on in the HIV epidemic (Larsson et al., 1989, Werner et al., 
1988). Confirming those early reports, a 2003 survey of the data from 16 published studies 
suggested that, despite adequate dietary intake, the average tryptophan blood level in HIV 
infection is almost 30% below that of normal uninfected individuals (Murray, 2003). This has 
been unambiguously attributed to increased oxidation of tryptophan, one outcome of which leads 
to the de novo synthesis of nicotinamide adenine dinucleotide (NAD+), a form of vitamin B3, 
niacin. This is a long and inefficient synthesis, which requires pyridoxal phosphate (PLP, the 
active form of vitamin B6) at the third step. Under normal conditions of health, typically less 
than 2% of dietary tryptophan is converted to NAD+ by this pathway (Murray, 2003). 
 
Intermediates of oxidative tryptophan metabolism have also been implicated in neurotoxicity, 
potentially contributing to AIDS dementia (Heyes et al., 1992). These include glutamate, 
quinolinic acid and xanthurenic acid, which is produced from kynurenine under conditions of 
inadequate vitamin B6, and has been shown to be a pro-apoptotic molecule (Malina et al., 2001). 
 
The phenomenon of tryptophan oxidation is of particular significance for the immunodeficiency 
associated with HIV infection, because in other contexts, a local deficit of tryptophan resulting 
from tryptophan oxidation impairs T-cell function, leading to immunological tolerance; this has 
been called “immunosuppression by starvation” (Mellor and Munn, 1999). This is exploited by 
the maternal immune system to induce fetal tolerance during pregnancy. Mellor and Munn have 
published a series of studies (Mellor et al., 2002, Mellor and Munn, 1999, Mellor and Munn, 
2001, Munn et al., 1999) elucidating the mechanism whereby induction of oxidative metabolism 
of tryptophan in certain immune cells (e.g., macrophages and dendritic cells) appears to trigger 
cell cycle arrest in nearby lymphocytes, preventing T-cell proliferation, leading to immune 
tolerance of the fetus. They call this immunosuppression by starvation, because they hypothesize 
that “tryptophan deletion” is the underlying mechanism (Mellor and Munn, 1999, Murray, 2003). 
Thus, tryptophan deletion in HIV infection would also be expected to contribute to 
immunosuppression. 
 
Tryptophan deletion via induction of IDO by the Th1 cytokine interferon-γ can also be used by 
the immune system to starve a pathogen — this is well established in the case of certain nonviral 
intracellular pathogens, e.g. Toxoplasma gondii, as reviewed by Murray (2003). In the case of 
HIV-1, the viral proteins tat and nef have been shown to induce IDO, possibly contributing to the 
tryptophan depletion observed in AIDS. The possibility that this is a deliberate viral strategy 
contributing to immunosuppression has been suggested (Murray, 2003). 
 
Paradoxically, despite the increased metabolism of tryptophan during HIV infection (Larsson et 
al., 1989, Werner et al., 1988), which could result in increased niacin synthesis, there is an 
associated intracellular deficiency of niacin, i.e. NAD+ (Brown et al., 1991), creating a state of 
“intracellular pellagra” (Murray et al., 1995), the induction of which may involve both virus and 
host factors (Murray, 2003). 
 
A pilot study by Murray et al. (2001) clearly demonstrated that the reduction in serum tryptophan 
levels induced by HIV infection can be countered by high-dose niacin supplemention. 
Presumably, correction of the state of “intracellular pellagra” leads to decreased demand for 
tryptophan oxidation for de novo NAD+ synthesis (Murray, 1999). It is also possible that the 
high doses of nicotinamide used in this study could lead to inhibition of PARP, thus further 
reducing NAD+ depletion and the need for tryptophan oxidation. 
 
2.3. Biological oxidation as a common factor 
 
Note that excessive oxidation is a common factor in all of the above: 
 
• Selenium deficiency or depletion leads to impaired glutathione function and oxidative 
stress, which is also increased by viral infection and cytokine activation (see below); 
• This can contribute to depletion of glutathione via oxidation of its key component 
cysteine to sulfate, leading to negative sulfur balance; 
• Oxidation of tryptophan is the first step in the tryptophan deletion pathway, which can 
directly contribute to immunosuppression, and, 
• Finally, the tryptophan deletion seen in HIV infection can be seen in part as a 
compensatory response to niacin depletion resulting from oxidative stress (explained 
below; remember that tryptophan oxidation is the first step in the de novo niacin synthesis 
pathway, an extremely inefficient biosynthesis that is required when niacin levels are 
inadequate). 
 
3. Other biochemical pathways contributing to or linking oxidative stress and tryptophan 
metabolism 
 
3.1. Arginine metabolism, peroxynitrite, and regulation of T-cell proliferation and apoptosis 
 
Arginine metabolism contributes to many important areas of biochemistry and physiology, such 
as regulation of vascular tone via the role of NO as the endothelial relaxing factor. The 
discussion here will be limited to two of its most important metabolizing enzymes, arginase and 
nitric oxide synthase (NOS), which are key components of an important immune regulatory 
system that has only been fully elucidated since 2000 (Bansal and Ochoa, 2003, Bronte et al., 
2003, Bronte and Zanovello, 2005, Mills, 2001). As illustrated in Fig. 1, iNOS (as well as its 
other NOS isoforms) converts arginine to citrulline and NO; this is in competition with arginase, 
which converts arginine to urea and ornithine, which can further be converted into proline or 
polyamines, both of which are important for growth and tissue remodeling; thus arginase is 
induced in trauma and other states where tissue healing is required (Bansal and Ochoa, 2003, 
Witte and Barbul, 2003). Extracellularly released arginase from granulocytes can induce 
profound suppression of T-cell proliferation (Munder et al., 2006), an effect which is also 
observed during pregnancy (Kropf et al., 2007). Arginase activity is significantly increased in the 
peripheral blood and placenta of pregnant women, leading to decreased placental arginine levels, 
and impaired T-cell functions (Kropf et al., 2007). This has striking similarities to the role of 
tryptophan metabolism in pregnancy. 
 
Since about 1995, it has been known that the NOS/arginase balance is under reciprocal 
regulation of Th1 and Th2 cytokines, with Th1 cytokines like TNF-α and interferon-γ being 
inducers of NOS, whereas Th2 cytokines like IL-4 and IL-10 inhibit NOS expression, and are 
potent inducers of arginase (Bronte et al., 2003, Modolell et al., 1995, Munder et al., 
1998, Munder et al., 1999). 
 
When both arginase and NOS2 (inducible NOS, iNOS) are induced (e.g., during inflammation), 
competition for arginine as a substrate leads to arginine depletion (Bronte et al., 2003). Under 
these arginine-limited conditions, synthesis of the reactive oxygen species (ROS) superoxide and 
peroxynitrite increases, which is counterintuitive, because production of NO, the precursor for 
peroxynitrite, will be diminished. Increased production of peroxynitrite by NOS under low 
arginine conditions has now been established for all three isoforms of NOS (Forstermann, 
2006, Xia et al., 1996, Xia and Zweier, 1997). As shown in Fig. 1, when inadequate arginine is 
available as substrate, the excess electrons generated by NOS are passed to oxygen to form 
superoxide, O2 − (Forstermann, 2006, Pou et al., 1992, Pou et al., 1999). Rapid combination of 
this superoxide with the NO that is formed from available arginine by the same enzyme results in 
the conversion of NOS into a machine for efficient production of peroxynitrite (Xia et al., 1996, 
Xia and Zweier, 1997), as seen in Fig. 1. This can result in peroxynitrite mediated cell injury 
(Xia et al., 1996), particularly in inflammatory diseases like asthma (Meurs et al., 2003, 
Ricciardolo et al., 2005). 
 
In the immune system, under the direction of Th1 and Th2 cytokines (Bronte et al., 2003), this 
arginine-based mechanism is used to regulate T-cell proliferation and apoptosis. Specifically, 
peroxynitrite generated under arginine-limited conditions acts to inhibit T-cell activation and 
proliferation (Brito et al., 1999), and can cause activated T-cells to undergo apoptosis (Brito et 
al., 1999, Bronte et al., 2003, Bronte and Zanovello, 2005). This consequence of arginine 
depletion is a direct threat to HIV, which preferentially replicates in activated cells. 
 
A critical role for arginine in HIV infection is supported by extensive evidence that arginine is of 
importance for both innate and acquired immune mechanisms (Bansal and Ochoa, 2003, Bronte 
et al., 2003, Bronte and Zanovello, 2005, De Santo et al., 2005, Mills, 2001). A role for NO in 
HIV pathogenesis is also well documented (Blond et al., 2000, Jimenez et al., 2001, Mannick et 
al., 1999, Mossalayi et al., 1999, Persichini et al., 1999, Torre et al., 2002). But peroxynitrite 
(ONOO−), not NO per se, is probably the key mediator in this case (Fig. 1). 
 
3.2. The poly(ADP-ribose) polymerase (PARP) complex is at the intersection of these systems 
 
The link between tryptophan depletion in HIV infection and the underlying antioxidant defects 
of selenium and sulfur/cysteine/glutathione is that oxidative stress can induce niacin/NAD+ 
depletion (Grant et al., 2000, Rawling et al., 1994). The mechanism by which oxidative stress 
leads to niacin depletion involves a cellular defense enzyme called the poly(ADP-ribose) 
polymerase (PARP), which is activated by oxidative damage to DNA (Cookson et al., 1998, 
Virag, 2005, Virag and Szabo, 2002). When a cell is oxidatively damaged beyond repair, PARP 
kicks into high gear to burn up (polymerize) all the intracellular NAD+, which leads to cell death 
via exhaustion of ATP. 
 
PARP detects single-stranded DNA breaks, triggering the transfer and polymerization of ADP-
ribose from NAD+ onto more than 40 nuclear proteins, particularly histones, certain transcription 
factors including NF-κB, and PARP itself, modulating their activities and functions. Activated 
by DNA breaks, PARP facilitates transcription, replication, and DNA base excision repair (Virag 
and Szabo, 2002). Because hydrogen peroxide and peroxynitrite in particular are highly effective 
in producing single-stranded breaks in DNA, oxidative stress is a potent inducer of PARP, 
therefore capable of inducing niacin/NAD+ depletion (Cookson et al., 1998, Koh et al., 2005, 
Tronov and Konstantinov, 2000, Virag, 2005). Thus, PARP is a point of intersection of the three 
biochemical systems or pathways described in Sections 2.1 Chronic oxidative stress, sulfur 
metabolism and selenium deficiency in HIV/AIDS, 2.2 Tryptophan depletion in HIV infection: 
immunosuppression induced by tryptophan metabolism and its role in, 3.1 Arginine metabolism, 
peroxynitrite, and regulation of T-cell proliferation and apoptosis (see Fig. 1 for a graphical 
illustration of this concept). 
 
4. The oxidative stress-induced niacin sink (OSINS) model for HIV pathogenesis 
 
Data reviewed in the previous section show how reactive oxygen species (ROS, e.g., 
peroxynitrite and peroxide), which increase under deficiency of arginine and selenium 
respectively, can cause NAD+/niacin depletion via DNA damage and PARP activation. The most 
important single idea of this article is that this can potentially lead to tryptophan oxidation for 
compensatory niacin synthesis. The resulting tryptophan deletion can then contribute to 
immunosuppression by established mechanisms, as reviewed in Section 2.2 (Mellor and Munn, 
1999, Moffett and Namboodiri, 2003, Murray, 2003), and also to T-cell loss via PARP-induced 
necrosis or apoptosis (Cookson et al., 1998, Koh et al., 2005, Tronov and Konstantinov, 2000). 
 
A role for oxidative stress can also explain the paradox of why there is an associated intracellular 
deficiency of niacin in HIV-infected cells, despite the increased metabolism of tryptophan, which 
should result in increased niacin synthesis. Oxidative stress creates a niacin “sink” that depletes 
both niacin and tryptophan. 
 
Thus, the oxidative stress-induced niacin sink (OSINS) model (Fig. 1) simply states that 
niacin/NAD depletion (requiring de novo synthesis from tryptophan) links oxidative stress and 
selenium to the observed tryptophan abnormalities and immunosuppression in HIV/AIDS. The 
OSINS model provides a mechanism whereby oxidative stress associated with HIV infection can 
contribute to immunosuppression via tryptophan deletion, as well as neurotoxicity via toxic 
tryptophan metabolites and ATP depletion. 
 
The process of viral infection itself, and inflammatory aspects of the immune response, are 
potential contributors to the oxidative stress seen in HIV infection (Israel and Gougerot-
Pocidalo, 1997, Valyi-Nagy and Dermody, 2005). Cytokine release and viral proteins like HIV 
env, tat and nef, have all been found to have pro-oxidant effects. But whatever the source of 
oxidative stress, there would be a net effect towards niacin depletion and compensatory 
tryptophan oxidation, with PARP activation as the primary link. 
 
5. Significance for the design of nutrient-based regimens as complementary therapies for 
HIV 
 
An important point of this analysis is to show that the need for certain nutrients in HIV infection 
may be largely secondary to an underlying defect that could be largely rectified by another 
nutrient, with antioxidants being the most fundamental to an effective regimen. Thus, in pilot 
studies in HIV-infected populations: 
 
• Supplementation with selenium alone has been shown to significantly restore glutathione 
levels (Delmas-Beauvieux et al., 1996), and a combined antioxidant supplement devoid 
of sulfur content still produced significant increases in glutathione (Batterham et al., 
2001). 
• In HIV-infected individuals, supplementation with niacinamide has been shown to lead to 
a 40% increase in serum tryptophan levels that were previously deficient, without any 
tryptophan supplementation (Murray et al., 2001). Presumably, correction of the state of 
“intracellular pellagra” leads to decreased demand for tryptophan oxidation for de 
novo niacin synthesis (Murray, 1999). 
 
Similarly, it is expected that supplementation with antioxidants should at least partially rectify 
the state of intracellular pellagra and tryptophan deficiency induced by HIV infection. 
Furthermore, there may be some combination of nutrients (e.g., inclusion of niacin along with 
antioxidants) that will act synergistically to reverse these infection-induced metabolic 
abnormalities. 
 
It is a specific prediction of the OSINS model that antioxidants should downregulate, inhibit or 
counteract IDO, since antioxidants will block PARP activation (i.e., act to plug the niacin 
“drain”), so that less compensatory niacin synthesis (via induction of IDO) would be required. 
There is at least one study that clearly demonstrates this, although the authors never mention 
PARP or the concept of compensatory niacin synthesis. Thomas et al. (2001) showed that IDO 
was inhibited by the antioxidant pyrrolidine dithiocarbamate, via a post-translational mechanism. 
 
6. Conclusions and significance 
 
An extensive body of evidence shows that certain nutrient deficiencies are associated with faster 
disease progression or increased mortality risk, and pilot studies suggest that micronutrient 
supplements (e.g. a daily multivitamin-mineral) can prolong survival in HIV/AIDS. Hence, there 
is a critical need to elucidate the cellular and viral mechanisms involved, with the aim of 
providing theoretical and empirical foundations for future clinical trials and supplementation 
programs involving micronutrients, amino acids and antioxidants as complementary therapies for 
HIV/AIDS. Such studies and programs would be highly relevant to a majority of the populations 
most affected by the HIV/AIDS pandemic, including 
 
• HIV+ populations in the developing world where sub-optimal nutrition is common, 
• Pediatric populations, which are more susceptible to the toxic side effects of antiretroviral 
therapy, 
• HIV+ pregnant women, because HIV infection can be exacerbated by the 
immunosuppression that is induced in pregnancy to avoid fetal rejection, via induction of 
tryptophan oxidation (Mellor et al., 2002) and arginine metabolism by the enzyme 
arginase (Kropf et al., 2007), 
• Drug abusing populations, which often manifest multiple nutritional deficiencies, as well 
as drug-induced oxidative stress, as reviewed by Taylor et al. (2000); 
• HIV-infected persons worldwide experiencing CNS infection, because antiretroviral 
drugs have limited ability to penetrate the blood-brain barrier (McGee et al., 2006), so 
nutritional therapies represent an alternative approach to diminishing the impact of HIV-
associated metabolic abnormalities in the brain. 
 
I have reviewed a body of evidence which shows that several underlying metabolic nutrient-
related abnormalities are present at both the cellular and systemic level, at least in untreated HIV 
infection (Sections 2.1 Chronic oxidative stress, sulfur metabolism and selenium deficiency in 
HIV/AIDS, 2.2 Tryptophan depletion in HIV infection: immunosuppression induced by 
tryptophan metabolism and its role in). Certain key biochemical pathways of amino acid and 
antioxidant micronutrient metabolism play critical roles in producing or mediating these 
abnormalities, thus contributing to HIV pathogenesis (Sections 3 Other biochemical pathways 
contributing to or linking oxidative stress and tryptophan metabolism, 4 The oxidative stress-
induced niacin sink (OSINS) model for HIV pathogenesis). 
 
The OSINS model provides a framework that could be a starting point for a systems biology 
approach to the discovery and optimization of “combination” nutraceutical therapies for HIV 
infection. The essence of the OSINS model is that, via DNA damage and PARP activation, 
whatever underlies or contributes to the antioxidant defect and increased oxidative stress 
associated with HIV infection, leads also to intracellular niacin depletion, and thereby to 
tryptophan depletion, with an end result of immunosuppression (Mellor and Munn, 1999, 
Moffett and Namboodiri, 2003, Murray, 2003), and also T-cell loss via PARP-induced cell death 
(Cookson et al., 1998, Koh et al., 2005, Tronov and Konstantinov, 2000). Since 
immunosuppression is the defining feature of HIV disease, this has the potential to be a 
fundamental mechanism of HIV pathogenesis. 
 
Hopefully, this analysis of the underlying mechanisms of action of nutrients, their deficiencies 
and their interactions in HIV infection may help to provide a rational basis for the design of 
clinical trials of micronutrients, amino acids and antioxidants as complementary therapies for 
HIV/AIDS. 
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